+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review

Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Takeda Pharmaceutical Co Ltd (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Co Ltd Key Recent Developments

  • Nov 18, 2022: Federal Lawsuit funded by we the patriots USA filed against Takeda Pharmaceuticals
  • Oct 27, 2022: Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
  • Sep 29, 2022: Strengthening Healthcare Systems to meet patients' need for plasma-derived therapies
  • Sep 19, 2022: Takeda signs virtual power purchase agreement with Enel North America to advance renewable energy production in the United States

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Takeda Pharmaceutical Co Ltd - Key Facts
  • Takeda Pharmaceutical Co Ltd - Key Employees
  • Takeda Pharmaceutical Co Ltd - Key Employee Biographies
  • Takeda Pharmaceutical Co Ltd - Major Products and Services
  • Takeda Pharmaceutical Co Ltd - History
  • Takeda Pharmaceutical Co Ltd - Company Statement
  • Takeda Pharmaceutical Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Takeda Pharmaceutical Co Ltd - Business Description
  • Product Category: Gastroenterology
  • Overview
  • Performance
  • Key Stats
  • Product Category: Hereditary Angioedema
  • Overview
  • Performance
  • Key Stats
  • Product Category: Neuroscience
  • Overview
  • Performance
  • Key Stats
  • Product Category: Oncology
  • Overview
  • Performance
  • Key Stats
  • Product Category: Other
  • Performance
  • Key Stats
  • Product Category: PDT Immunology
  • Overview
  • Performance
  • Key Stats
  • Product Category: Rare Hematology
  • Overview
  • Performance
  • Key Stats
  • Product Category: Rare Metabolic
  • Overview
  • Performance
  • Key Stats
  • Geographical Segment: Asia
  • Performance
  • Geographical Segment: Europe and Canada
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: Other Countries
  • Performance
  • Geographical Segment: Russia/CIS
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Takeda Pharmaceutical Co Ltd - Corporate Strategy
  • Takeda Pharmaceutical Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Takeda Pharmaceutical Co Ltd - Strengths
  • Takeda Pharmaceutical Co Ltd - Weaknesses
  • Takeda Pharmaceutical Co Ltd - Opportunities
  • Takeda Pharmaceutical Co Ltd - Threats
  • Takeda Pharmaceutical Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Takeda Pharmaceutical Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 18, 2022: Federal Lawsuit funded by we the patriots USA filed against Takeda Pharmaceuticals
  • Oct 27, 2022: Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
  • Sep 29, 2022: Strengthening Healthcare Systems to meet patients’ need for plasma-derived therapies
  • Sep 19, 2022: Takeda signs virtual power purchase agreement with Enel North America to advance renewable energy production in the United States
  • Sep 13, 2022: Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
  • Sep 08, 2022: Cryoport enters into strategic relationship with Takeda's BioLife plasma services
  • Jul 28, 2022: Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
  • Jul 11, 2022: Takeda places focus on personalized care and innovation for bleeding disorders at ISTH 2022
  • Jun 29, 2022: Takeda Announces New Assignments of Directors
  • Jun 29, 2022: Takeda Announces the Publication of its Annual Report on Form 20-F for FY2021
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Takeda Pharmaceutical Co Ltd, Key Facts
  • Takeda Pharmaceutical Co Ltd, Key Employees
  • Takeda Pharmaceutical Co Ltd, Key Employee Biographies
  • Takeda Pharmaceutical Co Ltd, Major Products and Services
  • Takeda Pharmaceutical Co Ltd, History
  • Takeda Pharmaceutical Co Ltd, Other Locations
  • Takeda Pharmaceutical Co Ltd, Subsidiaries
  • Takeda Pharmaceutical Co Ltd, Joint Venture
  • Takeda Pharmaceutical Co Ltd, Key Competitors
  • Takeda Pharmaceutical Co Ltd, Ratios based on current share price
  • Takeda Pharmaceutical Co Ltd, Annual Ratios
  • Takeda Pharmaceutical Co Ltd, Interim Ratios
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Takeda Pharmaceutical Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Takeda Pharmaceutical Co Ltd, Performance Chart (2018 - 2022)
  • Takeda Pharmaceutical Co Ltd, Ratio Charts
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc
  • Octapharma AG
  • Novo Nordisk AS
  • Taisho Pharmaceutical Holdings Co Ltd
  • Bayer AG
  • AstraZeneca Plc
  • Amgen Inc
  • Pfizer Inc
  • Grifols SA
  • F. Hoffmann-La Roche Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Celgene Corp
  • Biotest AG
  • Sumitomo Chemical Co Ltd
  • Merck & Co Inc
  • Bristol-Myers Squibb Co
  • Novartis AG
  • Novo Nordisk AS
  • F. Hoffmann-La Roche Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Celgene Corp
  • Biotest AG
  • AbbVie Inc
  • Octapharma AG
  • Sumitomo Chemical Co Ltd
  • Merck & Co Inc
  • Bristol-Myers Squibb Co
  • Pfizer Inc
  • Grifols SA
  • Novartis AG
  • Taisho Pharmaceutical Holdings Co Ltd
  • Bayer AG
  • AstraZeneca Plc
  • Amgen Inc